John E Nestler
Overview
Explore the profile of John E Nestler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
2147
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dinicola S, Unfer V, Facchinetti F, Soulage C, Greene N, Bizzarri M, et al.
Int J Mol Sci
. 2021 Oct;
22(19).
PMID: 34638926
Myo-inositol (myo-Ins) and D-chiro-inositol (D-chiro-Ins) are natural compounds involved in many biological pathways. Since the discovery of their involvement in endocrine signal transduction, myo-Ins and D-chiro-Ins supplementation has contributed to...
2.
Grossman C, Lemay M, Kang L, Byland E, Anderson A, Nestler J, et al.
Clin Teach
. 2021 Mar;
18(3):301-306.
PMID: 33684963
Background: Effective patient provider communication skills can be difficult and time-consuming to teach. Deliberate practice of communication skills through improvisational theatre exercises, with structured debriefing, can provide a solution for...
3.
Facchinetti F, Unfer V, Dewailly D, Kamenov Z, Diamanti-Kandarakis E, Lagana A, et al.
Trends Endocrinol Metab
. 2020 May;
31(6):435-447.
PMID: 32396844
This review details the physiologic roles of two insulin sensitizers, myo-inositol (MI) and d-chiro-inositol (DCI). In the human ovary, MI is a second messenger of follicle-stimulating hormone (FSH) and DCI...
4.
Facchinetti F, Appetecchia M, Aragona C, Bevilacqua A, Espinola M, Bizzarri M, et al.
Expert Opin Drug Metab Toxicol
. 2020 Mar;
16(3):255-274.
PMID: 32129111
: This Experts' opinion provides an updated scientific support to gynecologists, obstetricians, endocrinologists, nutritionists, neurologists and general practitioners on the use of Inositols in the therapy of Polycystic Ovary Syndrome...
5.
Unfer V, Nestler J, Kamenov Z, Prapas N, Facchinetti F
Int J Endocrinol
. 2018 Feb;
2017:6451082.
PMID: 29445397
[This corrects the article DOI: 10.1155/2017/8515703.].
6.
Le T, Wickham Rd E, Nestler J
Minerva Pediatr
. 2017 May;
69(5):434-443.
PMID: 28497664
Polycystic ovary syndrome (PCOS) is the most common disorder of androgen excess in women of reproductive age. The diagnosis of PCOS can be more challenging in adolescents than in adult...
7.
Unfer V, Nestler J, Kamenov Z, Prapas N, Facchinetti F
Int J Endocrinol
. 2017 May;
2017:8515703.
PMID: 28473852
No abstract available.
8.
Unfer V, Nestler J, Kamenov Z, Prapas N, Facchinetti F
Int J Endocrinol
. 2016 Nov;
2016:1849162.
PMID: 27843451
Polycystic ovary syndrome (PCOS) is a common endocrine disorder, with complex etiology and pathophysiology, which remains poorly understood. It affects about 5-10% of women of reproductive age who typically suffer...
9.
Pau C, Cheang K, Modi B, Kasippillai T, Keefe C, Shulleeta M, et al.
Pharmacogenomics
. 2016 Oct;
17(16):1765-1773.
PMID: 27790932
Aims: Variants in genes encoding metformin transport proteins and the ATM gene are associated with metformin response. We hypothesized that these gene variants contribute to variable metformin treatment response in...
10.
Cheang K, Sistrun S, Morel K, Nestler J
Int J Endocrinol
. 2016 Oct;
2016:7631804.
PMID: 27721826
A deficiency of D-chiro-inositol-inositolphosphoglycan mediator (DCI-IPG) may contribute to insulin resistance in polycystic ovary syndrome (PCOS). Whether the relationship between impaired DCI-IPG release and insulin resistance is specific to PCOS...